GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.40
Bid: 2.32
Ask: 2.54
Change: 0.04 (1.67%)
Spread: 0.22 (9.483%)
Open: 2.41
High: 2.41
Low: 2.34
Prev. Close: 2.39
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of major interests in shares

11 Oct 2010 14:30

RNS Number : 1948U
Immupharma PLC
11 October 2010
 



For immediate release

11 October 2010

 

Immupharma plc

 

TR-1: Notification of major interests in shares

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

 

Immupharma plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation:

Pictet Overseas Trust Corporation Limited

4. Full name of shareholder(s)  (if different from 3.):

See Above

 

5. Date of the transaction and date on which the threshold is crossed or reached:

 

6th October 2010

6. Date on which issuer notified:

7th October 2010

7. Threshold(s) that is/are crossed or reached:

 

3%

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights

Direct

Indirect

Direct

Indirect

 

Ordinary Shares GB0033711010

2,020,000

2,020,000

2,461,000

2,461,000

0

3.02%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial instrument

 

Expiration date

 

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

 

% of voting rights

N/A

N/A

N/A

N/A

N/A

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial instrument

 

 

Exercise price

 

Expiration date

 

Exercise/ Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

N/A

N/A

N/A

N/A

 

N/A

 

Nominal

Delta

N/A

N/A

Total (A+B+C)

Number of voting rights

Percentage of voting rights

2,461,000

3.02%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

Not Applicable

14. Contact name:

Katrina Montgomery, Legal & Compliance, Pictet Overseas Trust Corporation Limited

15. Contact telephone number:

+1 242 302 22 22

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLXFLFFBBFBFBZ
Date   Source Headline
21st Dec 20177:05 amRNSGrant of Options
21st Dec 20177:00 amRNSLast patient completes dosing in LupuzorT Trial
28th Nov 201712:00 pmRNSHolding(s) in Company
24th Nov 20171:32 pmRNSGrant of Options
2nd Nov 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
16th Oct 20173:29 pmRNSHolding(s) in Company
4th Oct 20177:00 amRNSCompletion of Lanstead Sharing Agreement
27th Sep 20177:00 amRNSInterim Results
26th Sep 20177:00 amRNSPreparation of Lupuzor'sT Regulatory Submissions
21st Sep 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
19th Sep 20177:00 amRNSNotification of Interim Results
18th Aug 20175:09 pmRNSAIM Rule 17 Notice
12th Jul 201711:00 amRNSGrant of Options
30th Jun 201712:04 pmRNSResult of AGM
30th Jun 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
7th Jun 20177:00 amRNSAnnual Report & Notice of AGM
1st Jun 20177:00 amRNSFinal Results
22nd May 20177:00 amRNSNotification of Full Year Results
17th May 20177:00 amRNSUpdate on Lupuzor Phase III Study
31st Mar 201710:17 amRNSNew Employee Share Option Plan & Grant of Options
31st Mar 20178:33 amRNSNew Employee Share Option Plan & Grant of Options
24th Mar 20177:00 amRNSImmuPharma to present at Master Investor Show
22nd Mar 20178:51 amRNSHolding(s) in Company
20th Mar 201711:41 amRNSHolding(s) in Company
20th Mar 20177:00 amRNSHolding(s) in Company
10th Mar 20173:52 pmRNS£4.1 Million Fund Raise via Accelerated Bookbuild
10th Mar 20177:00 amRNSAccelerated Bookbuild for the Issue of Equity
6th Mar 20173:55 pmRNSHolding(s) in Company
17th Feb 20172:04 pmRNSHolding(s) in Company
25th Jan 20177:00 amRNSUpdate on Lupuzor Phase III Study
24th Jan 20177:00 amRNSChange of Adviser
29th Dec 201610:54 amRNSHolding(s) in Company
22nd Dec 20167:00 amRNSUpdate on Lupuzor Pivotal Phase III Study
16th Nov 20167:00 amRNSUpdate on Cancer Compound IPP-204106 'Nucant'
9th Nov 20167:00 amRNSHolding(s) in Company
26th Oct 20163:42 pmRNSHolding(s) in Company
21st Oct 20165:13 pmRNSClose of Accelerated Bookbuild
21st Oct 20161:33 pmRNSProposed Accelerated Bookbuild for Vendor Placing
30th Sep 20167:00 amRNSHalf-year Report
14th Sep 20167:00 amRNSUPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
7th Sep 20167:00 amRNSUPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
21st Jul 20168:32 amRNSHolding(s) in Company
1st Jul 20163:52 pmRNSHolding(s) in Company
27th Jun 20164:41 pmRNSSecond Price Monitoring Extn
27th Jun 20164:35 pmRNSPrice Monitoring Extension
20th Jun 20167:00 amRNSAppointment of Joint Broker
9th Jun 20165:56 pmRNSHolding(s) in Company
8th Jun 20167:00 amRNSSymposium with Lupuzors Inventor Prof. S Muller
7th Jun 20167:00 amRNSEuropean Patients Commence Dosing in Lupuzor
2nd Jun 20165:26 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.